<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04747275</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00001385</org_study_id>
    <nct_id>NCT04747275</nct_id>
  </id_info>
  <brief_title>Use of Liquid Stable Levothyroxine in Trisomy 21 Pediatric Patients</brief_title>
  <official_title>Use of Liquid Stable Levothyroxine in Trisomy 21 Pediatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Mercy Hospital Kansas City</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Mercy Hospital Kansas City</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Children with levothyroxine (T21) have developmental delay and other functional&#xD;
      gastrointestinal (GI) issues that may negatively affect L-T4 tolerability and absorption. For&#xD;
      an age group unable to swallow tablets whole by mouth, tablets must be crushed and suspended&#xD;
      in water, breast milk or formula for administration in order to treat children with&#xD;
      hypothyroidism. For this age group, ease of administration may have a significant impact on&#xD;
      compliance and ability to remain euthyroid. We propose that Tirosint-SOL® will be more&#xD;
      favorably received due to ease of administration, improved tolerability and palatability,&#xD;
      therefore leading to improved adherence when compared to L-T4 tablets.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothyroidism is a common medical disorder in children with Trisomy 21 (T21). Treatment with&#xD;
      oral tablet levothyroxine (L-T4) is primarily used to treat this condition. However, children&#xD;
      with T21 have developmental delay and other functional gastrointestinal (GI) issues that may&#xD;
      negatively affect L-T4 tolerability and absorption. For an age group unable to swallow&#xD;
      tablets whole by mouth, tablets must be crushed and suspended in water, breast milk or&#xD;
      formula for administration in order to treat children with hypothyroidism. For this age&#xD;
      group, ease of administration may have a significant impact on compliance and ability to&#xD;
      remain euthyroid. Until recently, there was no liquid preparation of L-T4 in the United&#xD;
      States for use in children. Tirosint-SOL® (liquid stable L-T4) is now FDA-approved for use in&#xD;
      children. The Investigator proposes that Tirosint-SOL® will be more favorably received due to&#xD;
      ease of administration, improved tolerability and palatability, therefore leading to improved&#xD;
      adherence when compared to L-T4 tablets.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Phase 4, single-center, pilot, randomized, open-label, cross-over study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability as assessed by the CareCAT Tool</measure>
    <time_frame>4 months</time_frame>
    <description>Utilize medication tolerability questionnaire, Care Children's Acceptance Tool (CAT), to understand parental perceptions of liquid stable L-T4.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adherence to taking study medication</measure>
    <time_frame>4 months</time_frame>
    <description>Evaluate differences in compliance with liquid stable L-T4 compared to L-T4 tablet. Evaluated in percentage of days compliant.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Hypothyroidism</condition>
  <condition>Trisomy 21</condition>
  <arm_group>
    <arm_group_label>Maintain oral tablet levothyroxine (L-T4)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm 1: This arm will include patients on tablet L-T4. In each arm of the study, patients will be given an 8 week supply of either tablet L-T4 or liquid stable L-T4 Tirosint-SOL® . After 8 weeks patients will cross over to the second arm of the study for additional 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Receive liquid stable levothyroxine (L-T4) Tirosint-SOL®</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm 2: This arm will receive liquid stable L-T4 Tirosint-SOL® If currently on tablet L-T4, the dose will be the same for Tirosint-SOL® In each arm of the study, patients will be given an 8 week supply of either tablet L-T4 or liquid stable L-T4 Tirosint-SOL® . After 8 weeks patients will cross over to the first arm of the study for additional 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral tablet levothyroxine (L-T4)</intervention_name>
    <description>Investigation of tolerability, palatability, and adherence of maintained oral tablet levothyroxine (L-T4)</description>
    <arm_group_label>Maintain oral tablet levothyroxine (L-T4)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liquid stable levothyroxine (L-T4) Tirosint-SOL</intervention_name>
    <description>Investigation of tolerability, palatability, and adherence of liquid levothyroxine (L-T4)</description>
    <arm_group_label>Receive liquid stable levothyroxine (L-T4) Tirosint-SOL®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Trisomy 21 children age 2 months to less than 5 years of age&#xD;
&#xD;
          -  Prior confirmed diagnosis of congenital or acquired hypothyroidism&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Gestational age ≤ 35 weeks, concomitant anticonvulsant medications, history of&#xD;
             nonadherence with medication or medical visit schedule&#xD;
&#xD;
          -  Subjects must be able to take oral medication, no G-tube or parental fed subjects&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>4 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Matthew Feldt, DO</last_name>
    <phone>816-960-8803</phone>
    <email>mmfeldt@cmh.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Casey McClain, MPH</last_name>
    <phone>816-960-8877</phone>
    <email>clmcclain@cmh.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Orlich, RN</last_name>
      <phone>816-960-8847</phone>
      <email>sworlich@cmh.edu</email>
    </contact>
    <contact_backup>
      <last_name>Casey McClain, MHA</last_name>
      <phone>816-547-5474</phone>
      <email>clmcclain@cmh.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew Feldt, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 3, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tolerability</keyword>
  <keyword>Adherence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Down Syndrome</mesh_term>
    <mesh_term>Hypothyroidism</mesh_term>
    <mesh_term>Trisomy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

